Abstract:Neurodegenerative diseases are characterized by extensive loss of function or death of brain cells, hampering the life quality of patients. Brain-targeted drug delivery is challenging, with a low success rate this far. Therefore, the application of targeting ligands in drug vehicles, such as lipid-based and polymeric nanoparticles, holds the promise to overcome the blood-brain barrier (BBB) and direct therapies to the brain, in addition to protect their cargo from degradation and metabolization. In this review, we discuss the barriers to brain delivery and the different types of brain-targeting ligands currently in use in brain-targeted nanoparticles, such as peptides, proteins, aptamers, small molecules, and antibodies. Moreover, we present a detailed review of the different targeting ligands used to direct nanoparticles to specific brain cells, like neurons (C4-3 aptamer, neurotensin, Tet-1, RVG, and IKRG peptides), astrocytes (Aquaporin-4, D4, and Bradykinin B2 antibodies), oligodendrocytes (NG-2 antibody and the biotinylated DNA aptamer conjugated to a streptavidin core Myaptavin-3064), microglia (CD11b antibody), neural stem cells (QTRFLLH, VPTQSSG, and NFL-TBS.40–63 peptides), and to endothelial cells of the BBB (transferrin and insulin proteins, and choline). Reports demonstrated enhanced brain-targeted delivery with improved transport to the specific cell type targeted with the conjugation of these ligands to nanoparticles. Hence, this strategy allows the implementation of high-precision medicine, with reduced side effects or unwanted therapy clearance from the body. Nevertheless, the accumulation of some of these nanoparticles in peripheral organs has been reported indicating that there are still factors to be improved to achieve higher levels of brain targeting. This review is a collection of studies exploring targeting ligands for the delivery of nanoparticles to the brain and we highlight the advantages and limitations of this type of approach in precision therapies.

Non-viral gene delivery and therapeutics targeting to brain

Progress on brain-targeting non-viral gene delivery systems

Non‐viral Nucleic Acid Delivery to the Central Nervous System and Brain Tumors

Research Advances in Brain-Targeted Nanoscale Drug Delivery System

Nucleic Acids-based Nanotherapeutics Crossing the Blood Brain Barrier

Drug Delivery to the Brain Across the Blood-Brain Barrier Using Nanomaterials.

Nucleic acid drug vectors for diagnosis and treatment of brain diseases

Utilizing Multifaceted Approaches to Target Drug Delivery in the Brain: From Nanoparticles to Biological Therapies

Viral vectors for gene delivery to the central nervous system

Gene Delivery with Viral Vectors for Cerebrovascular Diseases

Strategies and materials of "SMART" non-viral vectors: Overcoming the barriers for brain gene therapy

Current Advances in Vehicles for Brain Gene Delivery

Nanocarriers As a Powerful Vehicle to Overcome Blood-Brain Barrier in Treating Neurodegenerative Diseases: Focus on Recent Advances

Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides

Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy

Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration

Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System

Brain-targeted nanoparticle drug delivery systems:research advances

Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands

Brain Delivery Using Nanotechnology

Micro‐Nanocarriers Based Drug Delivery Technology for Blood‐Brain Barrier Crossing and Brain Tumor Targeting Therapy (small 45/2022)